CardioDx, a Palo Alto, CA-based cardiovascular genomic diagnostics company, has closed a $60m round of equity financing.
New investors Longitude Capital, J.P. Morgan, Acadia Woods Partners, Artiman Ventures, and Bright Capital, as well as existing backers, which include Kleiner, Perkins, Caufield & Byers, Mohr Davidow Ventures, TPG Biotech, Intel Capital, Pappas Ventures, DAG Ventures, Asset Management Group and GE Capital, participated in the round.
The company intends to use the funding to expand reimbursement coverage in the United States for its blood-based gene expression test for obstructive coronary artery disease (Corus™ CAD), and to continue to develop new products in the field of cardiovascular genomic diagnostics.
In conjunction with the funding, Patrick Enright, managing director, Longitude Capital, joins the company’s board of directors.
Led by CEO David Levison, CardioDx develops clinically validated tests that are designed to empower clinicians to better tailor care to patients affected by coronary artery disease, cardiac arrhythmia and heart failure.